Abstract: The present application relates to novel 6-hydrogen-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present application relates to novel heterocyclyl- and heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present application relates to novel pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present application relates to novel pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazinecarboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: Embodiments of the present invention provide a system and method for determining a supply intensity metric (“SIM”) for benchmarking hospital supply expenses and for determining a supply expense target for opportunity identification based on the types and proportions of patients treated at a hospital. The SIM is a metric that may be used by hospitals to evaluate their supply chain or overall supply expenditures, and set goals for supply expense reduction. The SIM can be based on the number of patients in each DRG and an average supply expense for each DRG determined from a plurality of hospitals. A supply expense target may be based on, at least in part, a hospital's predicted inpatient supply expense, a non-chargeable expense, and a total outpatient supply expense.

Abstract: Embodiments of the present invention provide a system and method for determining a supply intensity metric (“SIM”) for benchmarking hospital supply expenses and for determining a supply expense target for opportunity identification based on the types and proportions of patients treated at a hospital. The SIM is a metric that may be used by hospitals to evaluate their supply chain or overall supply expenditures, and set goals for supply expense reduction. The SIM can be based on the number of patients in each DRG and an average supply expense for each DRG determined from a plurality of hospitals. A supply expense target may be based on, at least in part, a hospital's predicted inpatient supply expense, a non-chargeable expense, and a total outpatient supply expense.